Search
Search Constraints
You searched for: Author/Creator Ordentlich, Peter- Ordentlich, Peter [remove] 6
- Immunotherapy -- Periodicals 4
- Tumors -- Immunological aspects -- Periodicals 4
- 616.99406105 3
- Cancer -- Immunological aspects -- Periodicals 3
- Cancer -- Immunotherapy -- Periodicals 3
- 616.994 2
- 616.079 1
- AE adverse event -- ALT alanine aminotransferase -- AST aspartate aminotransferase -- bid twice a day -- c-KIT tyrosine-protein kinase KIT -- CCL2 C-C motif chemokine ligand 2 -- cGVHD chronic graft-versus-host disease -- CLE cutaneous lupus erythematous -- CPK creatine phosphokinase -- CRC colorectal cancer -- CSF1 colony-stimulating factor 1 -- CSF1R colony-stimulating factor 1 receptor -- CSF1Ri colony-stimulating factor 1 receptor inhibitors -- CTX-1 C-terminal telopeptide -- DLT dose-limiting toxicity -- DOR duration of response -- dt-TGCT diffuse-type tenosynovial giant cell tumor -- ECM extracellular matrix -- FLT3 Fms-related receptor tyrosine kinase 3 -- GAG glycosaminoglycans -- GBM glioblastoma multiforme -- GGT gamma glutamyltransferase -- GIST gastrointestinal stromal tumor -- HA hyaluronic acid -- HNSCC head and neck squamous cell carcinoma -- IL-34 interleukin 34 -- IPF idiopathic pulmonary fibrosis -- irRECIST immune-related response evaluation criteria in solid tumors -- LDH lactate dehydrogenase -- mAb monoclonal antibody -- M-CSF macrophage colony-stimulating factor -- MMP matrix metalloprotease -- MTD maximum tolerated dose -- mTOR mammalian target of rapamycin -- NSCLC non-small cell lung cancer -- NTX N-terminal telopeptide -- OBD optimal biological dose -- ORR overall response rate -- PD pharmacodynamic -- PD-1 programmed cell death 1 -- PD-L1 programmed death ligand 1 -- PDAC pancreatic ductal adenocarcinoma -- PDGFRα/β platelet-derived growth factor receptor α/β -- PK pharmacokinetic -- PR partial response -- RA rheumatoid arthritis -- RANO response assessment in neuro-oncology -- RECIST v1.1 response evaluation criteria in solid tumors, version 1.1 -- RP2D recommended phase 2 dose -- SD stable disease -- TAM tumor-associated macrophage -- TEAE treatment-emergent adverse event -- TGCT tenosynovial giant cell tumor -- TGFβ transforming growth factor β -- TME tumor microenvironment -- TRAE treatment-related adverse event -- TVS tumor volume score 1
- Allergy and Immunology -- Periodicals 1
- Breast cancer -- entinostat -- exemestane -- histone deacetylase inhibitors -- HLA-DR -- immune checkpoint receptor -- immune subsets -- monocyte -- myeloid-derived suppressor cell -- regulatory T cell 1